The film is a descriptive time-lapse journey about the magical, mysterious and medicinal world of fungi and their power to heal, sustain an contribute to the regeneration of life on Earth that began 3.5 billion years ago.
Imagine an organism that feeds you, heals you, reveals secrets of the universe and could help save the planet. You'll see it through the eyes of mycologists, like renowned Paul Stamets, about the unlimited potential of fungi in the fields of food, medicine, expanding consciousness, bioremediation, neurogenesis and treating end-of-life anxiety.

Mixing comedy with a thorough investigation of psychedelics, the film explores the pros, cons, science, history, future, pop cultural impact, and cosmic possibilities of hallucinogens. The documentary features comedic tripping stories from A-list actors, comedians, and musicians. Star-studded reenactments and trippy animations bring their surreal hallucinations to life.
'Have a Good Trip' tackles the big questions: Can psychedelics have a powerful role in treating depression, addiction, and helping us confront our own mortality? Are we all made of the same stuff? Is love really all we need? Can trees talk?

A ground-breaking new trial at Imperial College London sees, for the first time ever under controlled conditions, a psychedelic drug tested head-to-head against a standard antidepressant as a treatment for depression. The film follows a pioneering team of scientists and psychotherapists as they compare the effects of psilocybin (the active ingredient of magic mushrooms) with an antidepressant on a small group of participants with clinical depression.
This is scientific research at its most cutting edge. With over seven million people being prescribed antidepressants each year in England alone, this drug trial is an important milestone in understanding a completely different treatment for depression. How do psychedelic drugs measure up against the industry-standard antidepressants that have been popular since the 1990s? The empirical results of the trial are explored alongside the participants’ powerful lived experience.

The final episode of this series looks at what happens to the brain when someone uses psychedelic drugs. It looks at how psychedelic drugs may be useful in dealing with anxiety in cancer survivors and serious depression. It explores the history of psychedelics and examines early medical experimentation with the drug. It also discussed why psychedelics were banned and examines how they affect the brain.

This highly anticipated psychedelic docuseries showcases what these substances teaches people about consciousness, dying, addiction, depression and transcendence. Filmmaker Alex Gibney and best-selling author Michael Pollan present it in four parts, each focused on a different mind-altering substance: LSD, psilocybin, MDMA, and mescaline. With Pollan as our guide, we journey to the frontiers of the new psychedelic renaissance -- and look back at almost-forgotten historical context -- to explore the potential of these substances to heal and change minds as well as culture.
The first chapter is a great introduction to the topic of LSD, from its 1943 origins to today's microdosing trend, for those who don’t already know a lot about the subject, and a fun and entertaining refresher on LSD for even experts in the field. The show takes us on a journey through the history of the powerful compound, from its discovery and its early medical use, to secret CIA mind-control studies, the counterculture and its banning, and finally to our current renaissance. It includes amazing clips of LSD’s inventor Albert Hofmann and powerful personal testimonies of individuals who have healed their suffering through LSD.

Magic mushrooms, long considered sacred by the Indigenous Mazatec in Mexico, become the subject of scientific studies measuring the intense effects of its Psilocybin and its potential therapeutic use.
In the second episode, we are introduced to Ben, who’s battled with crippling Obsessive-Compulsive Disorder (OCD) his entire life. When he had his firstborn, Ben’s life became full of panic attacks regarding his son’s safety, and he knew something had to change. Ben signed up for a psilocybin-assisted therapy clinical trial which was testing whether the psychedelic could help people with severe OCD. In the session under the influence of psilocybin, Ben felt decomposed and eventually grew into a tree. While living as a tree, he saw his human self, playing with his child. Though this sounds scary, from Ben’s perspective, it was beautiful. He was one with the universe, seeing himself in the ultimate third-person perspective. Finally, he saw how it could be different if he didn’t let his OCD control him. And several months out, all the symptoms disappeared.
Ben’s story is one of many told in this series, which gives hope that help is right around the corner for the millions who suffer —often in silence— with debilitating mental disorders. But Michael Pollan’s work is showcasing the success stories. Often, even in the most successful trials, psychedelic-assisted therapy only helps up to a third of people enter remission. More frequently, patients are helped —sometimes substantially— but they still suffer with their illnesses and some people aren’t helped at all.